4,423 results match your criteria Expert opinion on pharmacotherapy[Journal]


Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery.

Expert Opin Pharmacother 2019 Feb 20:1-22. Epub 2019 Feb 20.

a Dipartimento di Scienze della Salute (DISSAL) , University of Genoa , Genoa , Italy.

Introduction: Patients undergoing open-heart surgery may suffer from postoperative complications, including severe infections. Antimicrobials to treat infectious complications in this population should be selected thoughtfully, taking into account three different and fundamental issues: (i) the site of infection; (ii) the suspected or proven causative agent and its susceptibility pattern; and (iii) the risk of suboptimal pharmacokinetic characteristics and potential toxicity of the chosen drug/s. Areas covered: The present narrative review summarizes the current and future antimicrobial options for the treatment of infections developing after open-heart surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574753DOI Listing
February 2019

The pharmacologic management of multiple myeloma in older adults.

Expert Opin Pharmacother 2019 Feb 20:1-16. Epub 2019 Feb 20.

d Department of Medicine, Division of Hematology and Oncology , Case Western Reserve University , Cleveland , OH , USA.

Introduction: Multiple myeloma is a disease predominately affecting older adults. Pivotal to treating older adults is understanding their physiologic differences compared to younger subjects and how the complexity of therapies has an impact upon this patient population. Areas covered: Herein, the authors address the efficacy of chemotherapy regimens, decision-making for older adults, chemotherapy-associated toxicity and the approach to management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1577822DOI Listing
February 2019

Agomelatine for depression: expanding the horizons?

Expert Opin Pharmacother 2019 Feb 13:1-10. Epub 2019 Feb 13.

a Department of Psychiatry , University of Melbourne, Austin Hospital , Heidelberg , Australia.

Introduction: Agomelatine is an antidepressant with unique pharmacological actions; it is both a melatonin agonist and selective serotonin antagonist. Both actions combined are necessary for antidepressant efficacy. Effects on melatonin receptors enable resynchronisation of disrupted circadian rhythms with beneficial effects on sleep patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574747DOI Listing
February 2019
1 Read

Zoledronic acid for the treatment of prostate cancer.

Expert Opin Pharmacother 2019 Feb 7:1-10. Epub 2019 Feb 7.

b Genitourinary Oncology , Inova Schar Cancer Institute , Fairfax , VA , USA.

Introduction: Prostate cancer remains the most common solid tumor afflicting men in the developed world. Metastatic prostate cancer is a source of great morbidity and mortality especially due to osseous involvement that gives rise to significant symptoms of pain or pathologic fractures or cord compression. Bisphosphonates had been widely used in the treatment of metastatic prostate bone metastases given their demonstrated benefit with a delay of skeletal-related events (SREs) but without prostate-specific antigen (PSA) response or overall survival benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574754DOI Listing
February 2019
1 Read

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes.

Expert Opin Pharmacother 2019 Feb 7:1-10. Epub 2019 Feb 7.

a Clinical Metabolic Physiology , Steno Diabetes Center Copenhagen , Gentofte , Denmark.

Introduction: Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571040DOI Listing
February 2019

Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.

Expert Opin Pharmacother 2019 Feb 7:1-11. Epub 2019 Feb 7.

c Services de Pharmacologie Clinique et Neurosciences, Centre d'Investigation Clinique CIC 1436, NS-Park/FCRIN Network, NeuroToul COEN Center , Université de Toulouse UPS, CHU de Toulouse, INSERM , Toulouse , France.

Introduction: L-threo-3,4-dihydroxyphenylserine (droxidopa), a pro-drug metabolized to norepinephrine in nerve endings and other tissues, has been commercially available in Japan since 1989 for treating orthostatic hypotension symptoms in Parkinson's disease (PD) patients with a Hoehn & Yahr stage III rating, as well as patients with Multiple System Atrophy (MSA), familial amyloid polyneuropathy, and hemodialysis. Recently, the FDA has approved its use in symptomatic neurogenic orthostatic hypotension (NOH). Areas covered: The authors review the effects of droxidopa in NOH with a focus on the neurodegenerative diseases PD, MSA, and pure autonomic failure (PAF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574746DOI Listing
February 2019
1 Read

Pharmacotherapeutic options for patients with refractory breast cancer.

Expert Opin Pharmacother 2019 Feb 7:1-11. Epub 2019 Feb 7.

a Medical Oncology & Breast Unit , "Antonio Perrino" Hospital , Brindisi , Italy.

Introduction: The development of resistance to therapy is a concern in all three subtypes of breast cancer (BC). Yet, outcomes of patients with BC have improved in the past few years thanks to a molecularly targeted approach and a greater understanding of the many mechanisms through which cancer cells adapt to evade drug therapies. Indeed, there have been a number of different and active treatment strategies for hormone receptor positive (HR+ and Her2 positive BC although triple-negative breast cancer treatment remains problematical because of the early onset of resistance to treatments and the limited availability of targeted treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574751DOI Listing
February 2019
2 Reads

Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?

Authors:
Jay Khastgir

Expert Opin Pharmacother 2019 Feb 6:1-8. Epub 2019 Feb 6.

a Swansea University Medical School , Abertawe Bro Morganwwg University Health Board , Swansea , Wales , UK.

Introduction: The use of antimuscarinic drugs is common in the management of the overactive bladder (OAB). Concerns have been raised over their use in the elderly population in whom the use of these drugs is highly prevalent, consequent to the reported link between these drugs and cognitive impairment and dementia. Areas covered: Recent publications have heightened concerns regarding antimuscarinic drug use in the elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574749DOI Listing
February 2019
1 Read

Choosing the right pharmacotherapeutic strategy for HIV maintenance in patients with alcohol addiction.

Expert Opin Pharmacother 2019 Feb 6:1-3. Epub 2019 Feb 6.

a College of Pharmacy, Department of Pharmaceutical Sciences , University of Tennessee Health Science Center , Memphis , TN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1574748DOI Listing
February 2019
2 Reads
3.534 Impact Factor

Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas.

Expert Opin Pharmacother 2019 Feb 6:1-11. Epub 2019 Feb 6.

a Academic Unit of Obstetrics and Gynecology , IRCCS Ospedale Policlinico San Martino , Genoa , Italy.

Introduction: Uterine leiomyosarcomas (ULMS) account for 1% of all uterine malignancies and for 30% of all uterine sarcomas. The preoperative diagnosis of ULMS is challenging for the physicians, as the symptoms of these tumors are often vague and nonspecific. Moreover, as ULMS have an aggressive biologic behavior, affected women frequently have very poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571042DOI Listing
February 2019
4 Reads
3.534 Impact Factor

An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.

Expert Opin Pharmacother 2019 Feb 5:1-12. Epub 2019 Feb 5.

a Department of Medicine , McMaster University , Hamilton , ON , Canada.

Introduction: Asthma is a common chronic airway inflammatory disease characterized by diverse inflammatory events leading to airway hyperresponsiveness and reversible airflow obstruction. Corticosteroids have been the mainstay for asthma treatment due to their broad anti-inflammatory actions; however, other medications such as phosphodiesterase 4 inhibitors also demonstrate anti-inflammatory activity in the airways. Areas covered: This review describes tissue expression of phosphodiesterase 4 in the airways, the different phosphodiesterase 4 isoenzymes identified, and the anti-inflammatory activities of phosphodiesterase 4 inhibition in asthma and related findings in chronic obstructive pulmonary disease (COPD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1570132DOI Listing
February 2019
3 Reads

Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease.

Expert Opin Pharmacother 2019 Feb 1:1-14. Epub 2019 Feb 1.

b Division of Respiratory Medicine , University Hospital "Tor Vergata" , Rome , Italy.

Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-dimensional approach, taking into account both symptoms of the patient and the number of acute exacerbations of COPD (AECOPDs). There are three main pharmaceutical classes currently available including long-acting muscarinic antagonists (LAMA), long-acting β-agonists (LABA) and inhaled corticosteroids (ICS). COPD is a major risk factor for most cardiovascular diseases, and cardiac comorbidities are very common in COPD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1570133DOI Listing
February 2019
1 Read

Current and emerging pharmacotherapy for emergency management of preeclampsia.

Expert Opin Pharmacother 2019 Feb 1:1-12. Epub 2019 Feb 1.

a Ritchie Centre, Department of Obstetrics and GynaecologySchool of Clinical Sciences , Monash University , Clayton , Australia.

Introduction: Preeclampsia is a disease specific to pregnancy characterised by new onset hypertension with maternal organ dysfunction and/or fetal growth restriction. It remains a major cause of maternal and perinatal morbidity and mortality. For fifty years, antihypertensives have been the mainstay of treating preeclampsia, reducing maternal morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1570134DOI Listing
February 2019
2 Reads

Current pharmacotherapy options for conduct disorders in adolescents and children.

Expert Opin Pharmacother 2019 Jan 31:1-13. Epub 2019 Jan 31.

h Townsville Clinical School, College of Medicine and Dentistry , James Cook University , Townsville , Australia.

Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD's complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561862DOI Listing
January 2019
7 Reads

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.

Expert Opin Pharmacother 2019 Mar 30;20(4):385-397. Epub 2019 Jan 30.

a Lady Davis Institute for Medical Research, Jewish General Hospital , McGill University AIDS Centre , Montréal , Québec , Canada.

Introduction: Current antiretroviral therapy is more effective and simpler than in previous times due to the development of new drugs with improved pharmacokinetic and pharmacodynamic profiles and the advent of single pill regimens with low toxicity that facilitate long-term adherence. The recent approval of the novel potent integrase strand-transfer inhibitor bictegravir (BIC) co-formulated with emtricitabine (FTC) and tenofovir alafenamide (TAF) in a fixed daily dose pill, B/F/TAF, adds to the list of single-tablet regimens available to treat HIV infection. Areas covered: This review provides an overview of the pharmacological and clinical information obtained from MEDLINE/PubMed publications and the latest international conferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1560423DOI Listing

Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice.

Expert Opin Pharmacother 2019 Jan 29:1-12. Epub 2019 Jan 29.

a Department of Molecular and Developmental Medicine , University of Siena , Siena , Italy.

Introduction: Binge eating disorder (BED) is the most common eating disorder and was newly recognized in 2013 in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). BED is frequently associated with obesity and the metabolic syndrome, as well as with other psychiatric diseases, such as mood (49%), anxiety (41%), and substance use (22%) disorders. BED is highly prevalent and carries a high burden of mental and physical illness and disability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571041DOI Listing
January 2019
1 Read

Pharmacotherapy for onychomycosis: new and emerging treatments.

Authors:
Shari R Lipner

Expert Opin Pharmacother 2019 Jan 28:1-11. Epub 2019 Jan 28.

a Department of Dermatology , Weill Cornell Medicine , New York , NY , USA.

Introduction: Onychomycosis is the most common nail disorder seen in clinical practice. It is not merely an aesthetic disorder and may cause significant disability and affect the quality of life. There are no strict guidelines for onychomycosis therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1571039DOI Listing
January 2019
1 Read

Efficacy of nab-paclitaxel in treating metastatic melanoma.

Authors:
Pol Specenier

Expert Opin Pharmacother 2019 Jan 28:1-6. Epub 2019 Jan 28.

a Department of Oncology , Antwerp University Hospital , Edegem , Belgium.

Introduction: Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical trials. Commonly used cytotoxics in these patients include paclitaxel, dacarbazine, platins, and temozolomide. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2019.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2019.1569628DOI Listing
January 2019
3 Reads

Choosing appropriate pharmacotherapy for drug-resistant HIV.

Expert Opin Pharmacother 2019 Jan 24:1-12. Epub 2019 Jan 24.

a Divisione Malattie Infettive , Aziende Socio Sanitarie Territoriale Fatebenefratelli Sacco , Milano , Italy.

Introduction: Despite the potency of current antiretrovirals, some patients continue to struggle with the management of the treatment of HIV due to drug resistance-associated mutations. The underlying causes of these developments are usually drug adherence and drug availability as well as the economic affordability of those potent drugs in low to middle-income countries as well as in some industrialised countries. Viral replication, despite therapy, varies by region from 5 to 28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1570131DOI Listing
January 2019

Current antimicrobial management of community-acquired pneumonia in HIV-infected children.

Expert Opin Pharmacother 2019 Jan 21:1-14. Epub 2019 Jan 21.

a Department of Paediatrics and Child Health, Faculty of Health Sciences , University of Cape Town and Red Cross War Memorial Children's Hospital , Cape Town , South Africa.

Introduction: Community-acquired pneumonia is a leading cause of morbidity and mortality amongst HIV-infected infants and children. Polymicrobial infection is common and, due to the difficulties in confirming the etiology of pneumonia, empiric broad-spectrum antimicrobial therapy is frequently used. Areas covered: The author based this article on literature identified from PubMed. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561864DOI Listing
January 2019
6 Reads

Challenges of selecting pharmacotherapy for macular edema the need for better and combination therapies.

Expert Opin Pharmacother 2019 Mar 18;20(4):373-377. Epub 2019 Jan 18.

a Research Blue Ocean Clinical Research , Department of Vision Integrated Partners , Clearwater , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1559298DOI Listing
March 2019
1 Read

Capecitabine for the treatment of pancreatic cancer.

Expert Opin Pharmacother 2019 Mar 16;20(4):399-409. Epub 2019 Jan 16.

a Division of Hematology/Oncology , Tufts Medical Center - Tufts University School of Medicine , Boston , MA , USA.

Introduction: Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) which is converted to 5FU by a series of reactions catalyzed by different enzymes, the last of the enzymes being thymidine phosphorylase (TP). TP is found to be elevated in tumor cells in comparison to normal cells, which consequently tumor-localizes the production of 5-FU, thereby limiting its systemic toxicity. Today, capecitabine is extensively used for the treatment of many solid malignancies, with a particular focus in breast and gastrointestinal tumors, but also in pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1560422DOI Listing
March 2019
1 Read
3.534 Impact Factor

The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.

Expert Opin Pharmacother 2019 Jan 9:1-12. Epub 2019 Jan 9.

b Department of Interdisciplinary Intensive Care , Jagiellonian University Medical College , Krakow , Poland.

Introduction: Common opioid adverse effects (AE) of the gastrointestinal tract include opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OIBD) with traditional laxatives being of limited efficacy, having AEs and not addressing the pathophysiology of OIC or OIBD. Targeted treatment comprises of PAMORA (peripherally acting mu-opioid receptor antagonists) and a combination of an opioid receptor agonist with its antagonist, namely prolonged-release oxycodone with prolonged-release naloxone (OXN) tablets at a fixed ratio of 2:1. Oxycodone provides analgesia, whereas naloxone prevents binding or displaces it from opioid receptors located in the gut wall. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561863DOI Listing
January 2019
3 Reads

The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.

Expert Opin Pharmacother 2019 Feb 7;20(3):261-268. Epub 2019 Jan 7.

a Cardiology Clinic, Department of Cardiac, Thoracic and Vascular Sciences , University of Padua , Padua , Italy.

Introduction: Patients admitted with acute medical conditions are at prolonged risk for venous thrombosis. The efficacy and safety, and the appropriate duration of thromboprophylaxis have not been clearly determined. In recent years, direct coagulation factor inhibitors have been successfully tested for the prevention and treatment of arterial and venous thromboembolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1558209DOI Listing
February 2019
1 Read

Chemical pharmacotherapy for hospital-acquired pneumonia in the elderly.

Expert Opin Pharmacother 2019 Mar 7;20(4):423-434. Epub 2019 Jan 7.

a Infectious Diseases Department , University Hospital Vall d'Hebron, Autonomous University of Barcelona , Barcelona , Spain.

Introduction: Hospital-acquired pneumonia (HAP) is a potentially serious infection that primarily affects older patients. The number of patients affected by multidrug-resistant (MDR) bacteria is increasing, including infection from strains of Staphylococcus aureus, Enterobacteriaceae, and Pseudomonas aeruginosa. Areas covered: This article focuses specifically on HAP, excluding patients afflicted by ventilator-associated pneumonia (VAP). Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1559820DOI Listing
March 2019
6 Reads

Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

Expert Opin Pharmacother 2019 Jan 7:1-9. Epub 2019 Jan 7.

b Division of Endocrinology, Diabetes & Metabolism, Weill Cornell Medicine , Comprehensive Weight Control Center , New York , NY , USA.

Introduction: Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561867DOI Listing
January 2019
1 Read

Lenalidomide for the treatment of mantle cell lymphoma.

Expert Opin Pharmacother 2019 Jan 4:1-8. Epub 2019 Jan 4.

b Biotechnology Research Unit, AO , Cosenza , Italy.

Introduction: Although a variety of therapeutic schemes for Mantle Cell Lymphoma (MCL) have been attempted, the clinical outcome of patients continues to be unsatisfactory especially among patients with a very high-risk profile and in the relapsed/refractory setting. For this reason, recent clinical trials have explored novel approaches, either by the use of biological agents in chemotherapy-free schedules or by integrating them with chemoimmunotherapy regimens. Areas covered: The efficacy of lenalidomide monotherapy and combination therapy established in clinical studies mainly involving relapsed/refractory MCL is reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561865DOI Listing
January 2019
3 Reads
3.534 Impact Factor

Pharmacotherapeutic options for co-morbid depression and alcohol dependence.

Expert Opin Pharmacother 2019 Jan 3:1-23. Epub 2019 Jan 3.

b Department of Psychiatry , Social Psychiatry and Psychotherapy, Hannover Medical School , Hannover , Germany.

Introduction: Depression and alcohol dependence are frequently co-morbid and among the most prevalent mental disorders. They are a serious global health problem with social, interpersonal, and legal interpolations. Among pharmacological alternatives, anti-craving compounds as well as antidepressants, antipsychotics, anticonvulsants, benzodiazepines, and beta-blockers have shown efficacy for depression as well as alcohol consumption. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561870DOI Listing
January 2019
6 Reads

An update on the topical and oral therapy options for treating pediatric atopic dermatitis.

Expert Opin Pharmacother 2019 Jan 2:1-9. Epub 2019 Jan 2.

a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Introduction: Atopic dermatitis (AD) is one of the most common childhood skin disorders. Multiple mechanisms contribute to the pathology of AD and treatment approaches are directed at these processes. Areas covered: The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561868DOI Listing
January 2019
6 Reads

Important decisions in choosing the pharmacotherapy for narcoleptics.

Expert Opin Pharmacother 2018 Dec 28:1-4. Epub 2018 Dec 28.

a Neurology Unit, Department of Neurosciences , University Hospital of Udine , Udine , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561861DOI Listing
December 2018
2 Reads

Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.

Expert Opin Pharmacother 2018 Dec 28:1-12. Epub 2018 Dec 28.

a Department of Oncology, Karmanos Cancer institute , Wayne State University , Detroit , MI , USA.

Introduction: Despite many efforts to improve the outcome of pancreatic ductal adenocarcinoma (PDAC), its prognosis remains poor, which is mostly related to late diagnosis and drug resistance. Improving systemic therapy is considered the major challenge in improving the outcome of this disease. Areas covered: This review covers novel chemotherapy and targeted agents in the treatment of PDAC, with a focus on advanced stage disease. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1561869DOI Listing
December 2018
6 Reads

Current synthetic pharmacotherapy for treatment resistant colorectal cancer: when urgent action is required.

Expert Opin Pharmacother 2018 Dec 28. Epub 2018 Dec 28.

Introduction: Colorectal cancer (CRC) remains a global concern. Fourteen antineoplastics are approved for metastatic CRC (mCRC); however, the 5-year overall survival remains poor for the overwhelming majority of patients. Poor outcomes continue to highlight the critical need for therapeutic advancement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1561866DOI Listing
December 2018
1 Read

Is there an appropriate strategy for treating co-morbid irritable bowel syndrome and bladder pain syndrome?

Expert Opin Pharmacother 2019 Mar 27;20(4):411-414. Epub 2018 Dec 27.

g Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS) , Tehran University of Medical Sciences , Tehran , Iran.

Introduction: Two of the most frequent components of chronic pelvic pain syndrome (CPPS) are irritable bowel syndrome (IBS) and bladder pain syndrome (BPS), characterized by considerable overlapping symptoms and pathophysiology. Currently, its management is challenging meaning there is high the demand for novel efficient therapeutics to aid patient care and to tackle the socioeconomic burden of IBS and BPS. As there are presently no sufficient treatment strategies, identifying the mechanisms that result in their main symptoms is the opportunity for developing appropriate therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1559821DOI Listing
March 2019
2 Reads

Pharmacotherapeutic strategies for standard treatment-resistant psoriasis.

Expert Opin Pharmacother 2019 Mar 27;20(4):443-454. Epub 2018 Dec 27.

a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Introduction: Psoriasis management includes a variety of treatments including localized therapies and systemic treatments; however, many patients report inadequate clinical response and resistance to therapy. Currently there is no treatment algorithm that incorporates effective strategies to tackle the various barriers leading to resistance. Areas covered: The authors evaluate the scope of resistance, the reasons it occurs, and provide the reader with strategies for overcoming resistance in both localized and systemic therapies for psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1559819DOI Listing
March 2019
1 Read

An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.

Expert Opin Pharmacother 2019 Feb 26;20(3):269-276. Epub 2018 Dec 26.

b 1st Division of Infectious Diseases , ASST Fatebenefratelli-Sacco , Milano , Italy.

Introduction: Approximately 2.1 million of the estimated 36 million infected with HIV are children or adolescents. International guidelines for HIV-1 Infection suggest starting antiretrovirals (ARV) at the moment of diagnosis. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1559299DOI Listing
February 2019
16 Reads

The use of polymyxins to treat carbapenem resistant infections in neonates and children.

Expert Opin Pharmacother 2019 Mar 21;20(4):415-422. Epub 2018 Dec 21.

e Paediatric Infectious Disease Research Group, Institute for Infection and Immunity , St George's University of London , London , UK.

Introduction: The incidence of healthcare-associated multidrug resistant bacterial infections, particularly due to carbapenem resistant organisms, has been on the rise globally. Among these are the carbapenem resistant Acinetobacter baumannii and Enterobacteriaceae, which have been responsible for numerous outbreaks in neonatal units. The polymyxins (colistin and polymyxin B) are considered to be the last resort antibiotics for treating such infections. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1559817DOI Listing
March 2019
1 Read

Efficacy and safety of alisporivir for the treatment of hepatitis C infection.

Expert Opin Pharmacother 2019 Mar 21;20(4):379-384. Epub 2018 Dec 21.

a Department of Gastroenterology , Grigore T. Popa University of Medicine and Pharmacy , Iasi , Romania.

Introduction: Alisporivir (ALV) (previously known as Debio 025) is a potent, pangenotypic host-targeting antiviral oral agent acting on cyclophilin A, which is necessary for HCV replication. Areas covered: This article reviews the therapeutic efficacy and safety of ALV for the treatment of HCV infection. Expert opinion: Direct-acting antivirals (DAAs) have revolutionized the HCV antiviral treatment paradigm with success rates well above 95% for all HCV genotypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1560424DOI Listing
March 2019
3 Reads

Is pharmacotherapy enough for urgent weight loss in severely obese patients?

Expert Opin Pharmacother 2019 Mar 21;20(4):367-371. Epub 2018 Dec 21.

a Department of Endocrinology & Nutrition , Clínica Universidad de Navarra , Pamplona , Spain.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1559818DOI Listing
March 2019
3 Reads

Correction.

Authors:

Expert Opin Pharmacother 2018 Dec 18. Epub 2018 Dec 18.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1558653DOI Listing
December 2018
1 Read

Mipomersen and its use in familial hypercholesterolemia.

Expert Opin Pharmacother 2019 Feb 10;20(2):127-131. Epub 2018 Dec 10.

a Division of Endocrinology, Metabolism, and Lipid Research, Department of Medicine , Washington University School of Medicine , St. Louis , MO , USA.

Introduction: Familial Hypercholesterolemia (FH) is an inherited disorder characterized by a defect in the binding and internalization of low-density lipoprotein (LDL) particles, resulting in markedly elevated LDL levels and premature atherosclerosis. It is one of the most common inherited disorders of lipid metabolism. Many FH patients, especially those with homozygous FH do not reach LDL goals with traditional LDL therapies and may require additional, less often used, therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1550071DOI Listing
February 2019
2 Reads

Pharmacotherapy for acute migraines in children and adolescents.

Expert Opin Pharmacother 2019 Mar 7;20(4):455-463. Epub 2018 Dec 7.

a Headache and Pain Unit, Department of Neurological , Motor and Sensorial Sciences; IRCCS San Raffaele Pisana , Rome , Italy.

Introduction: Migraine is increasingly recognized as an extremely burdensome and disabling disorder in both children and adolescents. A proper treatment plan is needed to improve the quality of life of both children and families as well as to minimize the risk of disease progression. Areas covered: This review focuses on the current pharmacotherapy for acute migraine in pediatric populations, taking into account specific considerations for those drugs tested in randomized, placebo-controlled trials (RCTs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1552941DOI Listing
March 2019
2 Reads

Correction.

Authors:

Expert Opin Pharmacother 2018 12 11;19(18):2095. Epub 2018 Dec 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2019.1556889DOI Listing
December 2018
1 Read

Therapeutic strategies for treating epilepsy during pregnancy.

Expert Opin Pharmacother 2019 Feb 10;20(3):323-332. Epub 2018 Dec 10.

a Department of Neurology , Beaumont Hospital , Dublin , Ireland.

Introduction: Counseling for women with epilepsy of childbearing potential surrounding pregnancy issues is of the utmost importance and should be done when antiepileptic medications are prescribed and reviewed regularly at clinic visits. Physicians must be familiar with risks associated with antiepileptic medication, and endeavor to minimize risks to a fetus while selecting best medications for epilepsy type. Areas covered: The authors discuss the role of folic acid, updated evidence relating to the occurrence of major congenital malformations and neurocognitive risks associated with antiepileptic medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1550073DOI Listing
February 2019
2 Reads

Pharmacotherapy for metastatic esophageal cancer: where do we need to improve?

Expert Opin Pharmacother 2019 Feb 7;20(3):357-366. Epub 2018 Dec 7.

a Department of Medicine , Perlmutter Cancer Center, NYU Langone Medical Center , New York , NY , USA.

Introduction: Esophageal cancer is a heterogeneous cancer comprised of differing cells of origin, molecular changes, and immune microenvironments. To date, most advances have been made in chemotherapy regimens where a one-size-fits-all approach is used. As a result, there remains a lack of tailored treatment options for such a heterogeneous cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1551881DOI Listing
February 2019
1 Read

Insight into the perioperative management of direct oral anticoagulants: concerns and considerations.

Expert Opin Pharmacother 2019 Mar 6;20(4):465-472. Epub 2018 Dec 6.

d Division of Cardiology, Department of Medicine and Therapeutics , The Chinese University of Hong Kong, Prince of Wales Hospital , Hong Kong , China.

Introduction: Direct oral anticoagulants (DOACs) have gained momentum in recent years in patients requiring anticoagulation for the prevention and management of venous thromboembolism and thromboembolic events caused by atrial fibrillation. The use of these agents involves potential bleeding complications, particularly during invasive procedures. With increasing use of DOACs, adequate knowledge regarding the perioperative management of patients on DOACs has become indispensable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1551879DOI Listing
March 2019
3 Reads

Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children.

Expert Opin Pharmacother 2019 02 6;20(3):241-244. Epub 2018 Dec 6.

a Biomedical Department of Internal Medicine and Medical Specialties , University of Palermo , Palermo , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1552942DOI Listing
February 2019
3 Reads

Clinical management of community-acquired pneumonia in young children.

Expert Opin Pharmacother 2019 Mar 3;20(4):435-442. Epub 2018 Dec 3.

b Department of Pediatrics , Federal University of Bahia School of Medicine , Salvador , Brazil.

Introduction: Community-acquired pneumonia (CAP) is the leading cause of mortality among children under 5 years worldwide. However, the choices of chemical therapy for the empirical treatment of CAP are frequently debated. Areas covered: The authors provide an update on the chemical management recommendations for childhood CAP. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1552257DOI Listing
March 2019
20 Reads

Novel pharmacotherapy for burn wounds: what are the advancements.

Expert Opin Pharmacother 2019 Feb 5;20(3):305-321. Epub 2018 Dec 5.

a Wellman Center for Photomedicine , Massachusetts General Hospital , Boston , MA , USA.

Introduction: The prognosis for severe burns has improved significantly over the past 50 years. Meanwhile, burns have become an affliction mainly affecting the less well-developed regions of the world. Early excision and skin grafting has led to major improvements in therapeutic outcomes. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1551880DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364296PMC
February 2019
6 Reads

Siponimod for the treatment of secondary progressive multiple sclerosis.

Expert Opin Pharmacother 2019 Feb 5;20(2):143-150. Epub 2018 Dec 5.

a Department of Neurosciences, University of Medicine and Pharmacy Carol Davila, Department of Neurology , Colentina Hospital , Bucharest , Romania.

Introduction: Multiple sclerosis (MS) is a chronic central nervous system immune-mediated disease with an important inflammatory component associated with focal demyelination and widespread neurodegeneration. In most cases, the clinical presentation is relapsing-remitting, followed by a secondary progressive phase, characterized by disability accrual unrelated to relapses. In a minority, the phenotype is progressive from the beginning. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1551363DOI Listing
February 2019
9 Reads

Bivalirudin during percutaneous coronary intervention in acute coronary syndromes.

Expert Opin Pharmacother 2019 Feb 4;20(3):295-304. Epub 2018 Dec 4.

a Department of Cardiology , Intensive care unit, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord , Marseille , France.

Introduction: Anticoagulant therapy is critical to prevent ischemic recurrences and complications in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). Unfractionated heparin (UFH), an injectable anticoagulant has several limitations: lack of predictability of its biological efficacy, platelets activation, heparin-induced thrombopenia and bleedings. Bivalirudin, a synthetic direct thrombin inhibitor has biological properties that promised better clinical outcome in ACS patients undergoing PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1551361DOI Listing
February 2019
8 Reads